Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis

Journal of Interferon and Cytokine Research

Volumn 35, Issue 6, 2015, Pages 411-420

  Ylldlrlm, Cansu ^a   Nieuwenhuis, Sylvia ^a   Teunissen, Paul F ^a   Horrevoets, Anton J G ^a   Van Royen, Niels ^a   Van Der Pouw Kraan, Tineke C T M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD31 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; COLLAGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; ELASTIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; GROWTH FACTOR; INTERLEUKIN 27; RECEPTOR; SCLEROPROTEIN; SIGNAL PEPTIDE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTING CELL; ARTERY LIGATION; ATHEROSCLEROSIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); ENDOTHELIUM CELL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MOLECULAR BIOLOGY; MONOCYTE; MONONUCLEAR CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; TISSUE PERFUSION; VASCULAR SMOOTH MUSCLE CELL; VASCULARIZATION; ANIMAL; AORTA VALVE STENOSIS; ARTERY; CYTOLOGY; DRUG EFFECTS; GENETICS; HEART MUSCLE ISCHEMIA; IMMUNOLOGY; METABOLISM; MORPHOGENESIS; PATHOLOGY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTIC VALVE STENOSIS; ARTERIES; CELL PROLIFERATION; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-BETA; MONOCYTES; MORPHOGENESIS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL ISCHEMIA; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84931047821     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0184     Document Type: Review

References (107)

1. Aplin AC, Ligresti G, Fogel E, Zorzi P, Smith K, Nicosia RF. 2014. Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by Toll-like receptors. Angiogenesis 17(1):147-161.
2. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. 1998. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 101(1):40-50.
3. Arslan F, de Kleijn DP, Pasterkamp G. 2011. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 8(5):292-300.
4. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. 2010. Myocardial ischemia/ reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel antitoll-like receptor-2 antibody. Circulation 121(1):80-90.
5. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100(5):2610-2615.
6. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM. 2007. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13(1-2):59-68.
7. Bastiaansen AJ, Karper JC, Wezel A, de Boer HC, Welten SM, de Jong RC, Peters EA, de Vries MR, van Oeveren-Rietdijk AM, van Zonneveld AJ, Hamming JF, Nossent AY, Quax PH. 2014. TLR4 accessory molecule RP105 (CD180) regulates monocyte-driven arteriogenesis in a murine hind limb ischemia model. PLoS One 9(6):e99882.
8. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. 2004. Human interferons alpha, beta and omega. Growth Factors 22(4):243-251.
9. Billottet C, Quemener C, Bikfalvi A. 2013. CXCR3, a doubleedged sword in tumor progression and angiogenesis. Biochim Biophys Acta 1836(2):287-295.
10. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. 2000. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36(7):2287-2295.
11. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990.
12. Bos CL, van Baarsen LG, Timmer TC, Overbeek MJ, Basoski NM, Rustenburg F, Baggen JM, Thiesen HJ, Dijkmans BA, van der Pouw Kraan TC, Voskuyl AE, Verweij CL. 2009. Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun 10(3):210-218.
13. Cai WJ, Koltai S, Kocsis E, Scholz D, Kostin S, Luo X, Schaper W, Schaper J. 2003. Remodeling of the adventitia during coronary arteriogenesis. Am J Physiol Heart Circ Physiol 284(1):H31-H40.
14. Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D, Dong Z. 2001. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 8(7):497-505.
15. Chen Z, Rubin J, Tzima E. 2010. Role of PECAM-1 in arteriogenesis and specification of preexisting collaterals. Circ Res 107(11):1355-1363.
16. Coelho LF, Magno de Freitas AG, Mennechet FJ, Blangy A, Uze G. 2005. Interferon-alpha and-beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A 102(33):11917-11922.
17. Conway EM, Collen D, Carmeliet P. 2001. Molecular mechanisms of blood vessel growth. Cardiovasc Res 49(3): 507-521.
18. de Groot D, Hoefer IE, Grundmann S, Schoneveld A, Haverslag RT, van Keulen JK, Bot PT, Timmers L, Piek JJ, Pasterkamp G, de Kleijn DP. 2011. Arteriogenesis requires toll-like receptor 2 and 4 expression in bone-marrow derived cells. J Mol Cell Cardiol 50(1):25-32.
19. de Groot D, Pasterkamp G, Hoefer IE. 2009. Cardiovascular risk factors and collateral artery formation. Eur J Clin Invest 39(12):1036-1047.
20. Dickson PV, Hamner JB, Streck CJ, Ng CY, McCarville MB, Calabrese C, Gilbertson RJ, Stewart CF, Wilson CM, Gaber MW, Pfeffer LM, Skapek SX, Nathwani AC, Davidoff AM. 2007. Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature. Mol Cancer Res 5(6): 531-542.
21. Dietrich N, Lienenklaus S, Weiss S, Gekara NO. 2010. Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. PLoS One 5(4): e10250.
22. Doring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, Soehnlein O, Busch M, Manca M, Koenen RR, Pelisek J, Daemen MJ, Lutgens E, Zenke M, Binder CJ, Weber C, Zernecke A. 2012. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 125(13):1673-1683.
23. Erdmann J, Vitale G, van Koetsveld PM, Croze E, Sprij-Mooij DM, Hofland LJ, van Eijck CH. 2011. Effects of interferons alpha/beta on the proliferation of human micro-and macrovascular endothelial cells. J Interferon Cytokine Res 31(5): 451-458.
24. Faber JE, Chilian WM, Deindl E, van Royen N, Simons M. 2014. A brief etymology of the collateral circulation. Arterioscler Thromb Vasc Biol 34(9):1854-1859.
25. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. 2002. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3(1):53-57.
26. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E. 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91(9): 852-859.
27. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. 2010. Novel therapeutic concepts: The epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J 31(6): 642-648.
28. Glaser J, Gonzalez R, Perreau VM, Cotman CW, Keirstead HS. 2004. Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res 77(5):701-708.
29. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made, I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, de Winther MP. 2010. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 12(2):142-153.
30. Groom JR, Luster AD. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89(2):207-215.
31. Hata T, Takahashi M, Hida S, Kawaguchi M, Kashima Y, Usui F, Morimoto H, Nishiyama A, Izawa A, Koyama J, Iwakura Y, Taki S, Ikeda U. 2011. Critical role of Th17 cells in inflammation and neovascularization after ischaemia. Cardiovasc Res 90(2):364-372.
32. Heil M. Schaper W. 2007. Insights into pathways of arteriogenesis. Curr Pharm Biotechnol 8(1):35-42.
33. Hoefer IE, Grundmann S, van Royen N, Voskuil M, Schirmer SH, Ulusans S, Bode C, Buschmann IR, Piek JJ. 2005. Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. Atherosclerosis 181(2):285-293.
34. Hoefer IE, van Royen N, Rectenwald JE, Deindl E, Hua J, Jost M, Grundmann S, Voskuil M, Ozaki CK, Piek JJ, Buschmann IR. 2004. Arteriogenesis proceeds via ICAM-1/Mac-1-mediated mechanisms. Circ Res 94(9):1179-1185.
35. Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25(3):349-360.
36. Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6(9):644-658.
37. Huang S, Bucana CD, Van Arsdall M, Fidler IJ. 2002. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21(16):2504-2512.
38. Huang Z, Yang Y, Jiang Y, Shao J, Sun X, Chen J, Dong L, Zhang J. 2013. Anti-tumor immune responses of tumorassociated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials 34(3):746-755.
39. Indraccolo S. 2010. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 43(3):244-247.
40. Ivashkiv LB, Donlin LT. 2014. Regulation of type I interferon responses. Nat Rev Immunol 14(1):36-49.
41. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. 2002. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8(4): 1258-1270.
42. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. 2010. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 120(4):1151-1164.
43. Javed A, Reder AT. 2006. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 110(1):35-56.
44. Kalliolias GD, Ivashkiv LB. 2010. Overview of the biology of type I interferons. Arthritis Res Ther 12 Suppl 1:S1-S9.
45. Kao J, Kobashigawa J, Fishbein MC, MacLellan WR, Burdick MD, Belperio JA, Strieter RM. 2003. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 107(15):1958-1961.
46. Kobayashi M, Saitoh S, Tanimura N, Takahashi K, Kawasaki K, Nishijima M, Fujimoto Y, Fukase K, kashi-Takamura S, Miyake K. 2006. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 176(10): 6211-6218.
47. Kumar H, Kawai T, Akira S. 2011. Pathogen recognition by the innate immune system. Int Rev Immunol 30(1):16-34.
48. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B. 2011. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407(2):348-354.
49. Luo MY, Yang BL, Ye F, Wu X, Peng S, Yi B, Wang W, Zhu W, Luo H, Wen JG, Cai WJ, Schaper J, Schaper W. 2011. Collateral vessel growth induced by femoral artery ligature is impaired by denervation. Mol Cell Biochem 354(1-2):219-229.
50. Ma Z, Qin H, Benveniste EN. 2001. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha 1. J Immunol 167(9):5150-5159.
51. McCarty MF, Bielenberg D, Donawho C, Bucana CD, Fidler IJ. 2002. Evidence for the causal role of endogenous interferonalpha/ beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 19(7):609-615.
52. Medina RJ, O'Neill CL, O'doherty TM, Knott H, Guduric-Fuchs J, Gardiner TA, Stitt AW. 2011. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol Med 17(9-10):1045-1055.
53. Meier P, Gloekler S, Zbinden R, Beckh S, de Marchi SF, Zbinden S, Wustmann K, Billinger M, Vogel R, Cook S, Wenaweser P, Togni M, Windecker S, Meier B, Seiler C. 2007. Beneficial effect of recruitable collaterals: A 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 116(9):975-983.
54. Nelissen I, Ronsse I, Van Damme J, Opdenakker G. 2002. Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. J Leukoc Biol 71(1):89-98.
55. Oh SS, Moon C, Kim DH, Song H, Park S, Fu Y, Kim KD. 2012. Adenovirally delivered IFN-beta exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation. Int J Mol Med 29(6):1153-1157.
56. Ohto U, Tanji H, Shimizu T. 2014. Structure and function of toll-like receptor 8. Microbes Infect 16(4):273-282.
57. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S. 2005. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 202(10):1333-1339.
58. Paludan SR, Bowie AG. 2013. Immune sensing of DNA. Immunity 38(5):870-880.
59. Park JA, Joe YA, Kim TG, Hong YK. 2006. Potentiation of antiglioma effect with combined temozolomide and interferon-beta. Oncol Rep 16(6):1253-1260.
60. Piccard H, Muschel RJ, Opdenakker G. 2012. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 82(3): 296-309.
61. Platanias LC. 2005. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375-386.
62. RayChaudhury A, Frischer H, Malik AB. 1996. Inhibition of endothelial cell proliferation and bFGF-induced phenotypic modulation by nitric oxide. J Cell Biochem 63(2):125-134.
63. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M. 2001. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107(1):53-63.
64. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. 2004. CXC chemokines: The regulatory link between inflammation and angiogenesis. Trends Immunol 25(4):201-209.
65. Schaper W, Scholz D. 2003. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 23(7):1143-1151.
66. Schirmer SH, Bot PT, Fledderus JO, van der Laan AM, Volger OL, Laufs U, Bohm M, de Vries CJ, Horrevoets AJ, Piek JJ, Hoefer IE, van Royen N. 2010. Blocking interferon {beta} stimulates vascular smooth muscle cell proliferation and arteriogenesis. J Biol Chem 285(45): 34677-34685.
67. Schirmer SH, Degen A, Baumhakel M, Custodis F, Schuh L, Kohlhaas M, Friedrich E, Bahlmann F, Kappl R, Maack C, Bohm M, Laufs U. 2012. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J 33(10): 1223-1231.
68. Schirmer SH, Fledderus JO, Bot PT, Moerland PD, Hoefer IE, Baan J, Jr., Henriques JP, van der Schaaf RJ, Vis MM, Horrevoets AJ, Piek JJ, van Royen N. 2008. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res 102(10):1286-1294.
69. Schirmer SH, van Nooijen FC, Piek JJ, van Royen N. 2009. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart 95(3):191-197.
70. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferongamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163-189.
71. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, Yoshimoto T. 2006. Antiangiogenic and antitumor activities of IL-27. J Immunol 176(12):7317-7324.
72. Shireman PK. 2007. The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 45 Suppl A:A48-A56.
73. Simons M. 2005. Angiogenesis: where do we stand now? Circulation 111(12):1556-1566.
74. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, Kazerooni EA, McCune WJ, Kaplan MJ. 2012. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 7(5):e37000.
75. Stabile E, Burnett MS, Watkins C, Kinnaird T, Bachis A, la Sala A, Miller JM, Shou M, Epstein SE, Fuchs S. 2003. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation 108(2):205-210.
76. Stabile E, Kinnaird T, la Sala A, Hanson SK, Watkins C, Campia U, Shou M, Zbinden S, Fuchs S, Kornfeld H, Epstein SE, Burnett MS. 2006. CD8 + T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4 + mononuclear cells through the expression of interleukin-16. Circulation 113(1):118-124.
77. Stephan D, San H, Yang ZY, Gordon D, Goelz S, Nabel GJ, Nabel EG. 1997. Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of betainterferon. Mol Med 3(9):593-599.
78. Stetson DB, Medzhitov R. 2006. Type I interferons in host defense. Immunity 25(3):373-381.
79. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM. 2003. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63(12):3370-3377.
80. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, Kelly PJ, Costelloe L, Tubridy N, Mills KH, Fletcher JM. 2011. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 25(6):1170-1181.
81. Szekanecz Z, Koch AE. 2009. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 51(1):1-7.
82. Takano S, Ishikawa E, Matsuda M, Yamamoto T, Matsumura A. 2014. Interferon-beta inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol 45(5):1837-1846.
83. Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ. 2008. Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res 28(12):733-740.
84. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC. 2002. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195(1):99-111.
85. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B, Cao G, DeLisser H, Schwartz MA. 2005. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 437(7057):426-431.
86. Urbich C, De Souza AI, Rossig L, Yin X, Xing Q, Prokopi M, Drozdov I, Steiner M, Breuss J, Xu Q, Dimmeler S, Mayr M. 2011. Proteomic characterization of human early pro-angiogenic cells. J Mol Cell Cardiol 50(2):333-336.
87. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. 2003. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108(20):2511-2516.
88. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL. 2006. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 7(6):522-531.
89. van den Borne P, Haverslag RT, Brandt MM, Cheng C, Duckers HJ, Quax PH, Hoefer IE, Pasterkamp G, de Kleijn DP. 2014a. Absence of chemokine (C-x-C motif) ligand 10 diminishes perfusion recovery after local arterial occlusion in mice. Arterioscler Thromb Vasc Biol 34(3):594-602.
90. van den Borne P, Quax PH, Hoefer IE, Pasterkamp G. 2014b. The multifaceted functions of CXCL10 in cardiovascular disease. Biomed Res Int 2014:1-11.
91. van der Laan AM, Piek JJ, van Royen N. 2009. Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol 6(8):515-523.
92. van der Laan AM, Schirmer SH, de Vries MR, Koning JJ, Volger OL, Fledderus JO, Bastiaansen AJ, Hollander MR, Baggen JM, Koch KT, Baan J, Jr., Henriques JP, van der Schaaf RJ, Vis MM, Mebius RE, van der Pouw Kraan TC, Quax PH, Piek JJ, Horrevoets AJ, van Royen N. 2012. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. Eur Heart J 33:1076-1084.
93. van der Pouw Kraan TC, van der Laan AM, Piek JJ, Horrevoets AJ. 2012. Surfing the data tsunami, a bioinformatic dissection of the proangiogenic monocyte. Vasc Pharmacol 56(5-6): 297-305.
94. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL. 2007. Rheumatoid Arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheumat Dis 66(8):1008-1014.
95. van Royen N, Hoefer I, Buschmann I, Heil M, Kostin S, Deindl E, Vogel S, Korff T, Augustin H, Bode C, Piek JJ, Schaper W. 2002. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 16(3):432-434.
96. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. 2001. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 49(3):543-553.
97. van Royen N, Piek JJ, Schaper W, Fulton WF. 2009. A critical review of clinical arteriogenesis research. J Am Coll Cardiol 55(1):17-25.
98. van Weel V, Toes RE, Seghers L, Deckers MM, de Vries MR, Eilers PH, Sipkens J, Schepers A, Eefting D, van Hinsbergh, V, van Bockel JH, Quax PH. 2007. Natural killer cells and CD4 + T-cells modulate collateral artery development. Arterioscler Thromb Vasc Biol 27(11):2310-2318.
99. Vilcek J. 2006. Fifty years of interferon research: aiming at a moving target. Immunity 25(3):343-348.
100. Wu S, Wu X, Zhu W, Cai WJ, Schaper J, Schaper W. 2010. Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis. Mol Cell Biochem 343(1-2):223-229.
101. Xiao HB, Zhou WY, Chen XF, Mei J, Lv ZW, Ding FB, Li GQ, Zhong H, Bao CR. 2012. Interferon-beta efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis. Gene Ther 19(10):1030-1034.
102. Yanai H, Savitsky D, Tamura T, Taniguchi T. 2009. Regulation of the cytosolic DNA-sensing system in innate immunity: A current view. Curr Opin Immunol 21(1):17-22.
103. Yoshida A, Anand-Apte B, Zetter BR. 1996. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 13(1-2):57-64.
104. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. 1995. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 76(6): 980-986.
105. Zhang LN, Velichko S, Vincelette J, Fitch RM, Vergona R, Sullivan ME, Croze E, Wang YX. 2008a. Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice. Atherosclerosis 197(1):204-211.
106. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL. 2008b. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/ beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 226:29-40.
107. Zheng H, Qian J, Carbone CJ, Leu NA, Baker DP, Fuchs SY. 2011. Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood 118(14):4003-4006.